Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
43,666,020
-
Total 13F shares
-
35,129,794
-
Share change
-
+2,965,117
-
Total reported value
-
$765,790,747
-
Put/Call ratio
-
150%
-
Price per share
-
$21.80
-
Number of holders
-
94
-
Value change
-
+$63,159,775
-
Number of buys
-
47
-
Number of sells
-
35
Institutional Holders of Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value (DNTH) as of Q4 2024
As of 31 Dec 2024,
Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value (DNTH) was held by
94 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
35,129,794 shares.
The largest 10 holders included
FMR LLC, Avidity Partners Management LP, Fairmount Funds Management LLC, Bain Capital Life Sciences Investors, LLC, Octagon Capital Advisors LP, RA CAPITAL MANAGEMENT, L.P., VR Adviser, LLC, BlackRock, Inc., TCG Crossover Management, LLC, and VANGUARD GROUP INC.
This page lists
94
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.